Description :IL-4 is a pleiotropic cytokine produced by activated T cells, mast cells, and basophils. IL-4 is apotent lymphoid cell growth factor which stimulates the growth and activation of certain B cellsand T cells. IL-4 is important for regulation of T helper subset development.
Preparation :The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™under optimal conditions.
Concentration: µg sizes: 0.2 mg/mL µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lotnumber in our Certificate of Analysis online tool.)
Storage & Handling :The antibody solution should be stored undiluted between 2°C and 8°C, and protected fromprolonged exposure to light. Do not freeze.
Application :ICFC - Quality tested
Recommended Usage :Each lot of this antibody is quality control tested by intracellular immunofluorescent staining withflow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.4 µgper million cells in 100 µl volume. For flow cytometric staining, the suggested use of this reagent is5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommendedthat the reagent be titrated for optimal performance for each application.
Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm isrecommended for detection, although filter optimization may be required depending on otherfluorophores used. Be sure to verify that your cytometer configuration and software setupare appropriate for detecting this channel. Refer to your instrument manual or manufacturerfor support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.
Application References(PubMed link indicatesBioLegend citation):
1. Shirai A, et al. 1994. Cytokine 6:329. (ELISA, Neut)
2. Abrams J. 1995. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.20. (ELISA, Neut)
3. Assenmacher M, et al. 1994. Eur. J. Immunol. 24:1097.
4. Openshaw P, et al. 1995. J. Exp. Med. 182:1357. (ICC)
5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.19. (ELISACapture)
6. Litton M, et al. 1994. J. Immunol. Methods 175:47. (IHC)
7. Andersson U, et al. 1999. Detection and quantification of gene expression. New York:SpringerVerlag. (IHC)
8. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
9. Hara M, et al. 2001. J. Immunol. 166:3789. (Neut)
10. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
11. Lawson BR, et al. 2007. J. Immunol. 178:5366.
12. Wang W, et al. 2007. J. Immunol. 178:4885. (Neut)
13. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
14. Ohnmacht C, et al. 2008. Blood 113:2816. PubMed
15. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
16. Zavorotinskaya T, et al. 2003. Mol. Ther. 7:155. (IP)
Product Citations:
1. Djokić V, et al. 2019. Front Immunol. 9:2891. PubMed
2. Yadava K et al. 2019. Elife. 8 pii: e44821. PubMed
3. Lorentsen KJ, et al. 2018. Nat Commun. 9:1679. PubMed
4. Li A, et al. 2020. J Virol. 94:00:00. PubMed
5. Bullard BL, et al. 2022. NPJ Vaccines. 7:65. PubMed
6. Peng L, et al. 2022. Cell Rep Med. 3:100634. PubMed